Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients

Megan E. Hartranft, Amber B. Clemmons, David L. Deremer, Vamsi Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Secondary failure of platelet recovery (SFPR) is a serious complication observed in approximately 20% of allogeneic hematopoietic stem cell transplant (HSCT) recipients. Although the standard therapeutic approach has been frequent platelet transfusions, romiplostim, a thrombopoietin receptor agonist, may have utility in treating SFPR. The primary objective of this single-center retrospective analysis was to assess effectiveness of romiplostim for SFPR and to evaluate patient factors which may influence clinical outcomes. The primary outcome measure of response was defined as achievement of platelet count ≥ 50 × 109/L without transfusions for ≥ 7 consecutive days. During the study period, 93 patients underwent HSCT and 13 (13.9%) received romiplostim for SFPR. Seven patients (53.8%) responded to romiplostim, requiring a median of three doses (range 1-6) to achieve independence from platelet transfusions. Disease relapse occurred in 38.5% of all patients, two responders and three nonresponders. Median survival post-HSCT was 753 days among responders and 266 days among nonresponders (p = 0.0375). No serious adverse events were reported, and rates of graft-versus-host disease did not increase following administration of romiplostim. Thrombopoietin receptor agonists including romiplostim offer a treatment option for persistent thrombocytopenia following HSCT. Positive clinical response to romiplostim post-HSCT is associated with improved outcomes.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of Oncology Pharmacy Practice
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hematopoietic Stem Cells
Treatment Failure
Blood Platelets
Transplants
Thrombopoietin Receptors
Platelet Transfusion
Graft vs Host Disease
romiplostim
Platelet Count
Thrombocytopenia
Outcome Assessment (Health Care)
Recurrence
Survival
Therapeutics

Keywords

  • Thrombocytopenia
  • allogeneic hematopoietic stem cell transplant
  • romiplostim
  • secondary failure of platelet recovery
  • thrombopoietin receptor agonist

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. / Hartranft, Megan E.; Clemmons, Amber B.; Deremer, David L.; Kota, Vamsi.

In: Journal of Oncology Pharmacy Practice, Vol. 23, No. 1, 01.01.2017, p. 10-17.

Research output: Contribution to journalArticle

@article{88d20616a63a42acb86e439c2f980dae,
title = "Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients",
abstract = "Secondary failure of platelet recovery (SFPR) is a serious complication observed in approximately 20{\%} of allogeneic hematopoietic stem cell transplant (HSCT) recipients. Although the standard therapeutic approach has been frequent platelet transfusions, romiplostim, a thrombopoietin receptor agonist, may have utility in treating SFPR. The primary objective of this single-center retrospective analysis was to assess effectiveness of romiplostim for SFPR and to evaluate patient factors which may influence clinical outcomes. The primary outcome measure of response was defined as achievement of platelet count ≥ 50 × 109/L without transfusions for ≥ 7 consecutive days. During the study period, 93 patients underwent HSCT and 13 (13.9{\%}) received romiplostim for SFPR. Seven patients (53.8{\%}) responded to romiplostim, requiring a median of three doses (range 1-6) to achieve independence from platelet transfusions. Disease relapse occurred in 38.5{\%} of all patients, two responders and three nonresponders. Median survival post-HSCT was 753 days among responders and 266 days among nonresponders (p = 0.0375). No serious adverse events were reported, and rates of graft-versus-host disease did not increase following administration of romiplostim. Thrombopoietin receptor agonists including romiplostim offer a treatment option for persistent thrombocytopenia following HSCT. Positive clinical response to romiplostim post-HSCT is associated with improved outcomes.",
keywords = "Thrombocytopenia, allogeneic hematopoietic stem cell transplant, romiplostim, secondary failure of platelet recovery, thrombopoietin receptor agonist",
author = "Hartranft, {Megan E.} and Clemmons, {Amber B.} and Deremer, {David L.} and Vamsi Kota",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1078155215612240",
language = "English (US)",
volume = "23",
pages = "10--17",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients

AU - Hartranft, Megan E.

AU - Clemmons, Amber B.

AU - Deremer, David L.

AU - Kota, Vamsi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Secondary failure of platelet recovery (SFPR) is a serious complication observed in approximately 20% of allogeneic hematopoietic stem cell transplant (HSCT) recipients. Although the standard therapeutic approach has been frequent platelet transfusions, romiplostim, a thrombopoietin receptor agonist, may have utility in treating SFPR. The primary objective of this single-center retrospective analysis was to assess effectiveness of romiplostim for SFPR and to evaluate patient factors which may influence clinical outcomes. The primary outcome measure of response was defined as achievement of platelet count ≥ 50 × 109/L without transfusions for ≥ 7 consecutive days. During the study period, 93 patients underwent HSCT and 13 (13.9%) received romiplostim for SFPR. Seven patients (53.8%) responded to romiplostim, requiring a median of three doses (range 1-6) to achieve independence from platelet transfusions. Disease relapse occurred in 38.5% of all patients, two responders and three nonresponders. Median survival post-HSCT was 753 days among responders and 266 days among nonresponders (p = 0.0375). No serious adverse events were reported, and rates of graft-versus-host disease did not increase following administration of romiplostim. Thrombopoietin receptor agonists including romiplostim offer a treatment option for persistent thrombocytopenia following HSCT. Positive clinical response to romiplostim post-HSCT is associated with improved outcomes.

AB - Secondary failure of platelet recovery (SFPR) is a serious complication observed in approximately 20% of allogeneic hematopoietic stem cell transplant (HSCT) recipients. Although the standard therapeutic approach has been frequent platelet transfusions, romiplostim, a thrombopoietin receptor agonist, may have utility in treating SFPR. The primary objective of this single-center retrospective analysis was to assess effectiveness of romiplostim for SFPR and to evaluate patient factors which may influence clinical outcomes. The primary outcome measure of response was defined as achievement of platelet count ≥ 50 × 109/L without transfusions for ≥ 7 consecutive days. During the study period, 93 patients underwent HSCT and 13 (13.9%) received romiplostim for SFPR. Seven patients (53.8%) responded to romiplostim, requiring a median of three doses (range 1-6) to achieve independence from platelet transfusions. Disease relapse occurred in 38.5% of all patients, two responders and three nonresponders. Median survival post-HSCT was 753 days among responders and 266 days among nonresponders (p = 0.0375). No serious adverse events were reported, and rates of graft-versus-host disease did not increase following administration of romiplostim. Thrombopoietin receptor agonists including romiplostim offer a treatment option for persistent thrombocytopenia following HSCT. Positive clinical response to romiplostim post-HSCT is associated with improved outcomes.

KW - Thrombocytopenia

KW - allogeneic hematopoietic stem cell transplant

KW - romiplostim

KW - secondary failure of platelet recovery

KW - thrombopoietin receptor agonist

UR - http://www.scopus.com/inward/record.url?scp=85006371387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006371387&partnerID=8YFLogxK

U2 - 10.1177/1078155215612240

DO - 10.1177/1078155215612240

M3 - Article

VL - 23

SP - 10

EP - 17

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 1

ER -